Related Experiment Video
Updated: Jul 30, 2026

08:17
Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa
Published on: September 27, 2018
Implantable gastric stimulation for weight loss
1Obesity Consult Center, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.
Summary
Electrical gastric stimulation using the implantable gastric stimulation (IGS) system offers a novel approach to obesity treatment. This minimally invasive technique shows promise for safe and effective weight loss without altering gastrointestinal anatomy.
Area of Science:
- Bariatric surgery
- Obesity treatment
- Medical devices
Background:
- Obesity is a global epidemic requiring effective weight management solutions.
- Traditional bariatric surgeries offer weight loss but carry risks of morbidity and anatomical changes.
- There is a need for novel, less invasive obesity treatments.
Purpose of the Study:
- To review the current experience and clinical data of the implantable gastric stimulation (IGS) system for obesity treatment.
- To evaluate the safety and efficacy of electrical gastric stimulation as a novel obesity intervention.
Main Methods:
- Review of preliminary worldwide investigations and clinical data on the IGS system.
- Description of the IGS system's operative technique and its non-anatomical alteration approach.
Main Results:
- The IGS system is a relatively new and novel approach to obesity treatment.
- Preliminary data suggest the IGS system is safe and effective for weight loss.
- The operative technique is simple and does not alter gastrointestinal anatomy.
Conclusions:
- Electrical gastric stimulation via the IGS system presents a promising alternative for obesity management.
- The IGS system demonstrates safety and efficacy in preliminary studies.
- Further review of the IGS system's current experience is warranted.
Related Concept Videos
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube through...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube through...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

